Fig. 3: Impact of adjunctive rosuvastatin versus standard TB treatment alone over 8 weeks of treatment in N = 24 participants. | Nature Communications

Fig. 3: Impact of adjunctive rosuvastatin versus standard TB treatment alone over 8 weeks of treatment in N = 24 participants.

From: PET-CT outcomes from a randomised controlled trial of rosuvastatin as an adjunct to standard tuberculosis treatment

Fig. 3

Blue dots represent Control group, Red dots represent Rosuvastatin group. Open dots represent Week 0 timepoint, coloured in dots represent Week 8 timepoint. A SUVmax [Week 0 median = 10.3 (IQR 6.4, 13.4), Week 8 median = 7.9 (IQR 5.8, 9.9) for Control, Week 0 median = 8.3 (IQR 5.1, 10.2), Week 8 median = 6.8 (IQR 3.9, 9.2) for Rosuvastatin], B TMV (cm3) [Week 0 median = 223.5 (68.8, 393.6), Week 8 median = 102.1 (IQR 32.1, 229.4) for control, Week 0 median =114.2 (IQR 37.4, 297.5), Week 8 median 27.3 (IQR 0.8, 135.0) for Rosuvastatin], C TLG [Week 0 median = 804.7 (IQR 183.1, 1358.7), Week 8 median = 308.5 (IQR 92.4, 771.4) for control, Week 0 median = 328.2 (IQR 1031, 987.4), Week 8 median = 79.8 (IQR 2.0, 443.3) for rosuvastatin], D Cavity diameter on CT (cm) [Week 0 median = 5.0 (IQR 2.7, 7.4), Week 8 median = 3.4 (IQR 1.4, 6.2) for Control, Week 0 median = 4.8 (IQR 1.2, 11.3), Week 8 median = 1.8 (IQR 0.6, 7.0) for Rosuvastatin], E Cavity volume on CT (cm3) [Week 0 median = 4.4 (IQR 1.7, 10.1), Week 8 median = 1.3 (IQR 0.3, 3.0) for Control, Week 0 median = 3.9 (IQR 1.0, 20.5), Week 8 median = 1.0 (IQR 0.3, 5.3) for Rosuvastatin], F Percentage of lung affected (%) [Week 0 median = 30 (IQR 20, 45), Week 8 median = 20 (IQR 15, 40) for Control, Week 0 median = 27.5 (IQR 17.5, 52.5), Week 8 median = 20 (IQR 5, 52.4) for Rosuvastatin]. Source data are provided as a Source Data file.

Back to article page